




RealRate

PHARMACEUTICAL 2016

Vanda Pharmaceuticals Inc
Rank 149 of 295



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Vanda Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 282%, being 19% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	166,547
Cost of Goods Sold	0
Intangible Assets	38,752
Liabilities, Current	51,317
Liabilities, Non-Current	3,706
Other Assets	3,181
Other Compr. Net Income	23
Other Expenses	36,434
Other Liabilities	25,000
Other Net Income	0
Other Revenues	110,245
Property and Equipment	4,570
Research and Development	29,145
Selling, General and Administrative Expense	84,531

Output Variable	Value in 1000 USD
Assets	213,050
Liabilities	80,023
Expenses	150,110
Revenues	110,245
Stockholders Equity	133,027
Net Income	-39,865
Comprehensive Net Income	-39,854
BaseVar	276,726
ECR before LimitedLiability	171%
Economic Capital Ratio	282%